Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease.
The present studies were undertaken to characterize Ag presentation by cultured human melanoma cell lines. Cell lines established from "biologically early" lesions of malignant melanoma were able to present the soluble Ag tetanus toxoid (TT) to autologous and HLA-DR-matched allogeneic, TT-immune T cell clones. Proliferation of T cell clones in response to Ag presented by primary melanoma peaked on day 2 of culture with Ag. Ag presentation was blocked by pretreatment of TT-pulsed and fixed melanoma cells with mAb against HLA-DR, but not HLA-DQ, HLA-DP, or HLA-ABC. Ag processing and presentation were inhibited by treating the melanoma cells with ammonium chloride. In parallel with previous findings from this laboratory demonstrating the inability of cell lines cultured from "advanced" primary or metastatic melanoma to induce autologous T cell proliferation, such cell lines also failed to present this exogenous Ag despite the presence of cell-surface HLA-class II molecules. Thus, in contrast to the finding in biologically early melanoma, none of the multiple TT-immune, T cell clones from autologous patients or HLA-DR matched donors was able to respond to TT presented by melanoma cells cultured from advanced disease. Co-incubation studies revealed that metastatic melanoma cells did not secrete inhibitory substances during the APC assay, however, they were able to process TT, rendering it "immunogenic" in the presence of fixed, autologous non-T cells. When fixed, autologous melanoma cells were assayed for their ability to present processed Ag; fixed cells of early but not advanced disease were able to present Ag in this setting, indicating that the presenting limb becomes flawed in the evolution of the metastatic phenotype. Finally, studies of chloroquine inhibition of the capacity of melanoma cells derived from early primary disease to stimulate autologous peripheral blood T cells suggest that such cells process and present tumor-associated Ag in the same fashion as the "model" Ag TT.
Alexander
M A
MA
Graduate Group in Immunology, University of Pennsylvania School of Medicine, Philadelphia 19104.
Bennicelli
J
J
Guerry
D
D
D000643:Ammonium Chloride; D000818:Animals; D000911:Antibodies, Monoclonal / Q000502:physiology; D000938:Antigen-Presenting Cells / Q000276:immunology*; D000951:Antigens, Neoplasm; D001667:Binding, Competitive; D002460:Cell Line; D002999:Clone Cells / Q000032:analysis / Q000145:classification; D000939:Epitopes / Q000276:immunology; D006681:HLA-D Antigens / Q000032:analysis / Q000235:genetics / Q000276:immunology; D006801:Humans; D007700:Kinetics; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000032:analysis / Q000145:classification; D008545:Melanoma / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D058950:Melanoma-Specific Antigens; D051379:Mice; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis; D010641:Phenotype; D013745:Tetanus Toxoid / Q000276:immunology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000939:Epitopes; D006681:HLA-D Antigens; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D013745:Tetanus Toxoid; D000643:Ammonium Chloride